Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editor's notes
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116446

Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.

M S Naylor, G W Stamp, W D Foulkes, D Eccles, and F R Balkwill

Biological Therapy Laboratory, Imperial Cancer Research Fund, London, England.

Find articles by Naylor, M. in: JCI | PubMed | Google Scholar

Biological Therapy Laboratory, Imperial Cancer Research Fund, London, England.

Find articles by Stamp, G. in: JCI | PubMed | Google Scholar

Biological Therapy Laboratory, Imperial Cancer Research Fund, London, England.

Find articles by Foulkes, W. in: JCI | PubMed | Google Scholar

Biological Therapy Laboratory, Imperial Cancer Research Fund, London, England.

Find articles by Eccles, D. in: JCI | PubMed | Google Scholar

Biological Therapy Laboratory, Imperial Cancer Research Fund, London, England.

Find articles by Balkwill, F. in: JCI | PubMed | Google Scholar

Published May 1, 1993 - More info

Published in Volume 91, Issue 5 on May 1, 1993
J Clin Invest. 1993;91(5):2194–2206. https://doi.org/10.1172/JCI116446.
© 1993 The American Society for Clinical Investigation
Published May 1, 1993 - Version history
View PDF
Abstract

The gene for tumor necrosis factor, TNF, was expressed in 45 out of 63 biopsies of human epithelial ovarian cancer. In serous tumors, there was a positive correlation between level of TNF expression and tumor grade. TNF mRNA was found in epithelial tumor cells and infiltrating macrophages, whereas TNF protein localized primarily to a subpopulation of macrophages within and in close proximity to tumor areas. mRNA and protein for the p55 TNF receptor gene localized to the tumor epithelium and tumor, but not to stromal macrophages. The p75 TNF receptor was confined to infiltrating cells. Cells expressing TNF mRNA were also found in ovarian cancer ascites and TNF protein was detected in some ascitic fluids. In 2 out of 12 biopsies of normal ovary, TNF mRNA was detected in a minority of cells in the thecal layer of the corpus luteum. Serum levels of TNF and its soluble receptor did not correlate with extent of TNF expression in matched biopsies. Northern and Southern analysis revealed no gross abnormality of the TNF gene. The coexpression of TNF and its receptor in ovarian cancer biopsies suggests the capacity for autocrine/paracrine action. TNF antagonists may have therapeutic potential in this malignancy.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2194
page 2194
icon of scanned page 2195
page 2195
icon of scanned page 2196
page 2196
icon of scanned page 2197
page 2197
icon of scanned page 2198
page 2198
icon of scanned page 2199
page 2199
icon of scanned page 2200
page 2200
icon of scanned page 2201
page 2201
icon of scanned page 2202
page 2202
icon of scanned page 2203
page 2203
icon of scanned page 2204
page 2204
icon of scanned page 2205
page 2205
icon of scanned page 2206
page 2206
Version history
  • Version 1 (May 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts